- Endogenous Glucose Production After Treatment with Canagliflozin and Liraglutide
- Empagliflozin Use in People with Type 2 and History of Coronary Artery Bypass Graft Surgery (CABG)
- Benefits of SGLT2 Inhibitors in Patients With or Without History of CVD
- What You and Your Patient Should Know to Prevent DKA
All of us are familiar with the value of SGLT-2 Inhibitors, and when we talk to patients we focus on the decreased re-absorption of glucose in the kidney and how that equals a decrease of about 70-100 carbs a day.
However, if you add a GLP-1 analog it is possible that you can get an increase in insulin production and decreased insulin resistance.
Looks like the combination of these 2 classes can address three of the biggest issues for our patients: food choices, insulin production and insulin resistance.
Pancreatic hormones, glucagon and insulin said partially responsible for unintended increase in glucose.
Research still limited in regard to SGLT2 inhibitor use and its ability to reduce CVD risk in patients after revascularization
Investigators analyze CVD-REAL study to determine impact of drug class on patients with T2D and HF history.
Teach patients what DKA is and how to prevent it. Include in your teaching that glucose can be normal or only slightly elevated and it can still happen. Teach that having an illness and/or dehydration increases this risk.